Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TFPI2 | P48307 | 2/20 | 0.39 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PPM1B | O75688 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14415445 | 0.91 | SLC6A3 (0.35) | LMNAGAATBXA2RSLC6A4SLC6A3 | |
| SCHEMBL5385156 | 0.87 | TBXA2R (0.36) | TBXA2RSLC6A4SLC6A3 | |
| SCHEMBL14415439 | 0.87 | TBXA2R (0.36) | TBXA2RSLC6A4SLC6A3 | |
| SCHEMBL5385148 | 0.87 | TBXA2R (0.36) | TBXA2RSLC6A4SLC6A3 | |
| SCHEMBL14415444 | 0.86 | KDM4E (0.35) | LMNAKDM4EPPM1BPTPN1PPP1CC | |
| SCHEMBL8988219 | 0.86 | TBXA2R (0.47) | PPM1BPTPN1PPP1CCTBXA2R | |
| SCHEMBL8870983 | 0.86 | TBXA2R (0.47) | PPM1BPTPN1PPP1CCTBXA2R | |
| SCHEMBL8870972 | 0.86 | TBXA2R (0.47) | PPM1BPTPN1PPP1CCTBXA2R | |
| SCHEMBL250371 | 0.82 | LMNA (0.45) | LMNAGAATFPI2PPP1CAKDM4E | |
| SCHEMBL250372 | 0.82 | LMNA (0.45) | LMNAGAATFPI2PPP1CAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588196-B1 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | ALLERGAN INC (US) | 2018-01-24 | — | — | EP | disclosed |
| EP-2588196-B1 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | ALLERGAN INC (US) | 2018-01-24 | — | — | EP | disclosed |
| US-8901159-B2 | Inhibition of inflammation by simultaneous blockade of multiple prostanoid receptors | ALLERGAN, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901159-B2 | Inhibition of inflammation by simultaneous blockade of multiple prostanoid receptors | ALLERGAN, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901159-B2 | Inhibition of inflammation by simultaneous blockade of multiple prostanoid receptors | ALLERGAN, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140187596-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187596-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187596-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2588196-A2 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | Allergan, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20120329843-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | ALLERGAN, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120329843-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | ALLERGAN, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120329843-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | ALLERGAN, INC. | 2012-12-27 | — | — | US | disclosed |
| WO-2012162416-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120077857-A1 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | ALLERGAN, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077857-A1 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | ALLERGAN, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077857-A1 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | ALLERGAN, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2012003477-A2 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | ALLERGAN, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003477-A2 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | ALLERGAN, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-7273883-B2 | Prostaglandin EP4 antagonist | ALLERGAN, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7217725-B2 | Prostaglandin D2 antagonist | ALLERGAN, INC. (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329843-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | FAAH, FAAH2, HRH2 | LMNA 3940/4885GAA 4284/4885TFPI2 1274/4885 |
| US-20140187596-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | FAAH, FAAH2, HRH2 | LMNA 3940/4885GAA 4284/4885TFPI2 1274/4885 |
| US-20120077857-A1 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | LTB4R2, LTB4R, PTGIR | LMNA 1321/4885GAA 4814/4885TFPI2 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.